Biogen Idec will provide the investment community an update on development programs and research in progress of the company, highlighting a broad and innovative portfolio of products includes six programs in the process of type approval tests.
"We have transformed the product portfolio in the last three years," said Cecil Pickett, Ph.D., President of Research and Development of Biogen Idec. "With 20 programs in Phase 2 and more advanced, our portfolio rivaling that of other larger companies and positions the company for solid growth."